Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $12.4 million.

  • Harvard Bioscience's Other Accumulated Expenses rose 2163.57% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year increase of 2163.57%. This contributed to the annual value of $9.4 million for FY2024, which is 1141.14% down from last year.
  • Per Harvard Bioscience's latest filing, its Other Accumulated Expenses stood at $12.4 million for Q3 2025, which was up 2163.57% from $12.5 million recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's Other Accumulated Expenses peaked at $12.5 million during Q2 2025, and registered a low of $6.6 million during Q1 2021.
  • Over the past 5 years, Harvard Bioscience's median Other Accumulated Expenses value was $9.4 million (recorded in 2024), while the average stood at $9.5 million.
  • In the last 5 years, Harvard Bioscience's Other Accumulated Expenses skyrocketed by 8358.7% in 2022 and then crashed by 3417.62% in 2023.
  • Harvard Bioscience's Other Accumulated Expenses (Quarter) stood at $10.8 million in 2021, then tumbled by 30.44% to $7.5 million in 2022, then skyrocketed by 41.88% to $10.6 million in 2023, then dropped by 11.41% to $9.4 million in 2024, then surged by 31.51% to $12.4 million in 2025.
  • Its Other Accumulated Expenses stands at $12.4 million for Q3 2025, versus $12.5 million for Q2 2025 and $11.4 million for Q1 2025.